Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers.
Yamakawa N, Tago F, Nakai K, Kitahara Y, Ikari S, Hojo S, Hall N, Aluri J, Hussein Z, Gevorkyan H, Maruyama T, Ishizaka S, Yagi T. Yamakawa N, et al. Among authors: tago f. Clin Pharmacol Drug Dev. 2023 Apr;12(4):363-375. doi: 10.1002/cpdd.1176. Epub 2022 Oct 11. Clin Pharmacol Drug Dev. 2023. PMID: 36219471 Clinical Trial.
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: tago f. Arthritis Rheumatol. 2021 Apr;73(4):587-595. doi: 10.1002/art.41555. Epub 2021 Feb 18. Arthritis Rheumatol. 2021. PMID: 33038062 Free PMC article. Clinical Trial.
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: tago f. Mod Rheumatol. 2021 Jul;31(4):783-789. doi: 10.1080/14397595.2020.1868675. Epub 2021 Feb 2. Mod Rheumatol. 2021. PMID: 33427546 Clinical Trial.
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: tago f. Mod Rheumatol. 2023 Dec 22;34(1):45-49. doi: 10.1093/mr/road005. Mod Rheumatol. 2023. PMID: 36680420 Clinical Trial.
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.
Tanaka Y, Kumanogoh A, Atsumi T, Ishii T, Tago F, Aoki M, Yamamuro S, Akira S. Tanaka Y, et al. Among authors: tago f. RMD Open. 2024 Sep 17;10(3):e004701. doi: 10.1136/rmdopen-2024-004701. RMD Open. 2024. PMID: 39289029 Free PMC article. Clinical Trial.
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.
Tanaka Y, Hoshino-Negishi K, Kuboi Y, Tago F, Yasuda N, Imai T. Tanaka Y, et al. Among authors: tago f. Immunotargets Ther. 2020 Nov 4;9:241-253. doi: 10.2147/ITT.S277991. eCollection 2020. Immunotargets Ther. 2020. PMID: 33178636 Free PMC article. Review.
15 results